Purpose We evaluated the prognostic value of immunotherapy-induced organ inflammation observed on (18)FDG PET in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs). Methods Data from patients with IIIB/IV NSCLC included in two different prospective trials were analyzed. (18)FDG PET/CT exams were...
-
2022 (v1)PublicationUploaded on: January 31, 2024
-
April 22, 2024 (v1)Journal article
Purpose Because of atypical response imaging patterns in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs), new biomarkers are needed for a better monitoring of treatment efficacy. The aim of this prospective study was to evaluate the prognostic value of volume-derived...
Uploaded on: January 13, 2025 -
June 19, 2024 (v1)Journal article
Abstract Aim To determine the long-term prognosis of immune-related response profiles (pseudoprogression and dissociated response), not covered by conventional PERCIST criteria, in patients with non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs). Methods 109 patients were prospectively included and underwent [...
Uploaded on: January 13, 2025 -
February 2020 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
July 23, 2020 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
September 2022 (v1)Journal article
Abstract Purpose We evaluated the prognostic value of immunotherapy-induced organ inflammation observed on 18 FDG PET in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs). Methods Data from patients with IIIB/IV NSCLC included in two different prospective trials were analyzed. 18 FDG PET/CT exams...
Uploaded on: December 4, 2022 -
September 30, 2020 (v1)Journal article
No description
Uploaded on: December 3, 2022 -
March 1, 2022 (v1)Journal article
Purpose - Methods - The IFCT 1703-R2D2 trial is a multicenter, nonrandomized phase II study. Patients with -mutated, advanced NSCLC who progressed after ≥ 1 platinum-based treatment were enrolled. Patients received pertuzumab at a loading dose of 840 mg and 420 mg thereafter; trastuzumab at an 8 mg/kg loading dose and 6 mg/kg thereafter; and...
Uploaded on: February 22, 2023 -
March 29, 2022 (v1)Journal article
The histological distinction of lung neuroendocrine carcinoma, including small cell lung carcinoma (SCLC), large cell neuroendocrine carcinoma (LCNEC) and atypical carcinoid (AC), can be challenging in some cases, while bearing prognostic and therapeutic significance. To assist pathologists with the differentiation of histologic subtyping, we...
Uploaded on: December 3, 2022